ClinicalTrials.gg
CompletedNCT00304512Updated Oct 3, 2018Results posted

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

A Phase 2 interventional study of migalastat HCl in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 6 sites in 6 countries. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-03.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
16th of 20
9 · median 20
Started
2006
with 3 others
Phase 2
6 of 20
none open now
Registered
4th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 16th largest by enrollment, is one of 4 that started in 2006, is one of 6 in phase 2, and was the 4th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.

Read the detailed description

This was a Phase 2, open-label study in female participants with Fabry disease. The study consisted of a 4-week screening period, during which participants' galactosidase (GLA) genotype was assessed for α-galactosidase A (α-Gal A) activity in response to migalastat. Participants were required to have α-Gal A activity responsive to migalastat. The study consisted of a 12-week treatment period, followed by an optional 36-week extension period. Participants received migalastat once every other day (QOD) for 12 weeks during the treatment period and the optional 36-week extension period for a total treatment duration of up to 48 weeks. Participants were stratified by α-Gal A enzyme activity (high >40%, and low ≤40%) then randomly assigned to receive migalastat at 1 of 3 specified dose levels (50, 150, or 250 milligrams [mg]).

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Amicus Therapeutics
  • AT1001
  • Galafold
  • Migalastat
  • Substrate
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females between 18 and 65 years of age (inclusive)
  • Heterozygous for Fabry disease
  • Had a confirmed diagnosis of Fabry disease with a documented missense gene mutation (individual or familial)
  • Had enhanceable enzyme activity based on in vitro tests
  • Were naïve to enzyme replacement therapy (ERT) and other therapies, except for palliative therapies for the signs and symptoms of Fabry disease, or stopped ERT for at least 18 weeks
  • Had end organ dysfunction, even minimal, demonstrated by abnormal (ECG) or evidence of left ventricular hypertrophy documented by echocardiogram or by cardiac ; or renal insufficiency documented by common clinical assessments such as creatinine and or by renal biopsy; or brain tissue dysfunction as documented by evidence of stroke (clinically or imaging); or peripheral nervous tissue dysfunction documented by complaints of intolerance to heat or cold, decreased vibratory sense and proprioception, decreased ability to perspire, or acroparesthesia.
  • Were willing to undergo 2 renal and 3 skin biopsies
  • Agreed to be sexually abstinent or practice an effective method of when engaging in sexual activity during the course of the study and for a period of 30 days following their completion of the study for women of .
  • Were willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating
  • History of organ transplant
  • History of significant disease other than Fabry disease (for example, end-stage renal disease; Class III or IV heart disease [per the classification]; current diagnosis of cancer, except for basal cell carcinoma of the skin; diabetes [unless ≤8]; or neurological disease that would have impaired the participant's ability to participate in the study)
  • Serum creatinine >176 micromoles/liter on Day -2
  • Screening 12-lead demonstrating interval >450 milliseconds
  • Pacemaker or other for magnetic resonance imaging scanning
  • Taking a medication prohibited by the protocol: Fabrazyme® (agalsidase beta), Replagal™ (agalsidase alfa), Glyset® (miglitol), Zavesca® (miglustat), or any experimental therapy for any indication
  • Participated in a previous clinical trial in the last 30 days
  • Any other condition which, in the opinion of the investigator would jeopardize the safety of the participant or impact the validity of the study results.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Migalastat Low Dose 50 mg

    Migalastat 50 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.

    Drug: migalastat HCl

  • Experimental
    Migalastat Middle Dose 150 mg

    Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.

    Drug: migalastat HCl

  • Experimental
    Migalastat High Dose 250 mg

    Migalastat 250 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.

    Drug: migalastat HCl

Interventions

06

What researchers measure

Primary outcomes

  1. Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 48 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Day 1 (after dosing) through Week 48

Secondary outcomes

  1. PK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat

    The AUC to the last measurable concentration (AUC0-t) was evaluated in plasma following a single oral dose of migalastat on Day 1 and following multiple oral doses on Day 14 (2 weeks) and Day 84 (12 weeks). All samples were collected on each dosing day.

    Time frame: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, and 10 hours (postdose)

  2. α-Gal A Activity In Leukocytes At Baseline, Week 12, And Week 48

    Leukocytes were isolated from whole blood and lysed, and α-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole \[nmol\] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. α-Gal A activity in leukocytes are presented by individual participants.

    Time frame: Baseline, Week 12 (end of treatment period), Week 48 (end of extension period)

07

Results

Posted Sep 7, 2018

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneMigalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mg
Started243
Safety population243
Pharmacokinetic (pk) population243
Pharmacodynamic (pd) population243
Completed243
Not completed000
Extension Period
Participant flow — Extension Period
MilestoneMigalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mg
Started243
Completed243
Not completed000

Outcome measures

PrimaryNumber Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 48 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Day 1 (after dosing) through Week 48
Reported as:
Count of participants · Participants
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)
ParticipantsMigalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mg
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)000
SecondaryPK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat

The AUC to the last measurable concentration (AUC0-t) was evaluated in plasma following a single oral dose of migalastat on Day 1 and following multiple oral doses on Day 14 (2 weeks) and Day 84 (12 weeks). All samples were collected on each dosing day.

Time frame:
0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, and 10 hours (postdose)
Reported as:
Geometric mean · nanograms*hours/milliliters (ng*hr/mL)
PK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat
nanograms*hours/milliliters (ng*hr/mL)Migalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mg
AUC0-t: Single Dose, Day 12628.9 ± 100.48941.6 ± 32.213217.2 ± 30.2
AUC0-t: Multiple Dose, Day 143191.6 ± 64.910637.9 ± 35.614850.6 ± 9.6
AUC0-t: Multiple Dose, Day 842300.3 ± 79.68581.9 ± 29.79970.3 ± 37.8
Secondaryα-Gal A Activity In Leukocytes At Baseline, Week 12, And Week 48

Leukocytes were isolated from whole blood and lysed, and α-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole \[nmol\] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. α-Gal A activity in leukocytes are presented by individual participants.

Time frame:
Baseline, Week 12 (end of treatment period), Week 48 (end of extension period)
Reported as:
Number · nmol 4-MU/hr/mg protein
α-Gal A Activity In Leukocytes At Baseline, Week 12, And Week 48
nmol 4-MU/hr/mg proteinMigalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mg
Participant 1: Baseline13.4——
Participant 1: Week 122.46——
Participant 1: Week 4826——
Participant 2: Baseline24.5——
Participant 2: Week 1235.8——
Participant 2: Week 4839.6——
Participant 3: Baseline—25.1—
Participant 3: Week 12—4.15—
Participant 3: Week 48—NA—
Participant 4: Baseline—6.39—
Participant 4: Week 12—18.4—
Participant 4: Week 48—16.1—
Participant 5: Baseline—17.3—
Participant 5: Week 12—5.85—
Participant 5: Week 48—22.2—
Participant 6: Baseline—24.6—
Participant 6: Week 12—12.6—
Participant 6: Week 48—46.5—
Participant 7: Baseline——3.25
Participant 7: Week 12——6.56
Participant 7: Week 48——4.83
Participant 8: Baseline——14.7
Participant 8: Week 12——23.3
Participant 8: Week 48——29.2
Participant 9: Baseline——13.1
Participant 9: Week 12——8.86
Participant 9: Week 48——7.58

Adverse events

Collected over Day 1 after dosing through Week 48 (end of extension period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Migalastat Low Dose 50 mg—0/2 (0%)2/2 (100%)
Migalastat Middle Dose 150 mg—1/4 (25%)4/4 (100%)
Migalastat High Dose 250 mg—0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventMigalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mg
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/21/40/3
Most frequent other events
Showing 10 of 71
Most frequent other events
EventMigalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mg
HeadacheNervous system disorders1/23/40/3
Sinus arrhythmiaCardiac disorders1/20/40/3
Abdominal discomfortGastrointestinal disorders1/20/40/3
Abdominal painGastrointestinal disorders1/21/40/3
DiarrhoeaGastrointestinal disorders1/20/40/3
NauseaGastrointestinal disorders1/20/40/3
VomitingGastrointestinal disorders1/21/40/3
Face oedemaGeneral disorders1/20/40/3
Oedema peripheralGeneral disorders1/21/40/3
Bronchitis acuteInfections and infestations1/20/40/3

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Migalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mgTotal
Mean49.0 ± 18.3844.8 ± 9.9544.0 ± 2.6545.4 ± 9.23
Sex: Female, Male
Sex: Female, Male(Participants)Migalastat Low Dose 50 mgMigalastat Middle Dose 150 mgMigalastat High Dose 250 mgTotal
Female2439
Male0000
08

Study locations

6 sites
  • Decatur, Georgia 30033, United States
  • Parkville, Victoria 3050, Australia
  • Porto Alegre, RS, 90035-903, Brazil
  • Montréal, H4J 1C5, Canada
  • Paris, 75015, France
  • Salford, M6 8HD, United Kingdom
09

References and documents

Publications

  • Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22. PubMed 27657681 ↗
  • Giugliani R, Waldek S, Germain DP, Nicholls K, Bichet DG, Simosky JK, Bragat AC, Castelli JP, Benjamin ER, Boudes PF. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol Genet Metab. 2013 May;109(1):86-92. doi: 10.1016/j.ymgme.2013.01.009. Epub 2013 Jan 26. PubMed 23474038 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2006 to primary completion in May 2008, 20 months.

Results were first posted in Sep 2018, 10 years 3 months after primary completion. A results delay was requested in Aug 2010.

Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2006
First posted
Mar 20, 2006
StartActual
Sep 7, 2006
Primary completionActual
May 9, 2008
CompletionActual
May 9, 2008
Results delay requested
Aug 17, 2010
Results first posted
Sep 7, 2018
Last update
Oct 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00304512
Responsible party
Sponsor
First posted
Mar 20, 2006
Start date
Sep 7, 2006
Primary completion
May 9, 2008
Completion
May 9, 2008
Results posted
Sep 7, 2018
Last update
Oct 3, 2018

Study contacts

Medical Monitor, Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion